I begge undersøgelser havde patienter, hvis kræft ikke påvirkede pladecellerne, imidlertid en længere overlevelsestid, hvis de fik Alimta, end hvis de fik et sammenligningspræparat.
However, in both studies, patients whose cancer was not affecting squamous cells had longer survival times if they received Alimta than if they received the comparator.